{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:02Z","timestamp":1792788602558,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of end-stage kidney disease (ESKD), cardiovascular events, and all-cause mortality in chronic kidney disease (CKD), regardless of diabetes or baseline renal function. However, patients with severely impaired kidney function or on dialysis have been excluded from landmark randomized clinical trials (RCTs). Several off-target mechanisms of SGLT2i could be involved in the cardiac protection of patients with ESKD in which the reduced nephron mass strongly diminishes the tubular effects of SGLT2i. However, available evidence in patients undergoing hemodialysis (HD) and peritoneal dialysis (PD) is limited thus leaving efficacy and safety in this population uncertain.<\/jats:p>\n                  <jats:p>Pharmacokinetic studies confirm that dapagliflozin is not dialyzable and shows no significant accumulation in dialysis patients. Small exploratory trials reported favorable cardiovascular and electrophysiological effects of SGLT2i in HD, while retrospective studies suggest they may preserve residual kidney function in incremental dialysis and improve volume status without major safety concerns. Large retrospective cohort analyses of patients starting dialysis showed lower risks of cardiovascular events and mortality in SGLT2i users compared with non-users. When treated with PD, no study has reported outcome data, and findings on efficacy were mixed with some studies showing increased ultrafiltration and lower blood pressure, while others showed no effect on peritoneal glucose transport.<\/jats:p>\n                  <jats:p>The theoretic protection against cardiovascular and mortality risk of SGLT2i must be confirmed by ongoing large-scale trials that will clarify the role of this class of drugs in dialysis populations.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf350","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T12:43:30Z","timestamp":1763124210000},"source":"Crossref","is-referenced-by-count":12,"title":["SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-2089","authenticated-orcid":false,"given":"Roberto","family":"Minutolo","sequence":"first","affiliation":[{"name":"Nephrology Unit at University of Campania \u201cLuigi Vanvitelli\u201d , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Nephrology Unit at University of Campania \u201cLuigi Vanvitelli\u201d , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Conte","sequence":"additional","affiliation":[{"name":"Nephrology Unit at University of Campania \u201cLuigi Vanvitelli\u201d , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Nephrology Unit at University of Campania \u201cLuigi Vanvitelli\u201d , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2026010204362462000_bib1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010204362462000_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010204362462000_bib3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010204362462000_bib4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"2026010204362462000_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2026010204362462000_bib6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010204362462000_bib7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","article-title":"Sodium\/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes","volume":"64","author":"De Nicola","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026010204362462000_bib8","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/jcm9072243","article-title":"Nephroprotection by SGLT2 inhibition: back to the future?","volume":"9","author":"De Nicola","year":"2020","journal-title":"J Clin Med"},{"key":"2026010204362462000_bib9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2026010204362462000_bib10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tem.2024.02.003","article-title":"Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors","volume":"35","author":"Mashayekhi","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"2026010204362462000_bib11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026010204362462000_bib12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2215\/CJN.0000000000000221","article-title":". Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation","volume":"18","author":"Heerspink","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026010204362462000_bib13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","article-title":"Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction","volume":"99","author":"Juni","year":"2021","journal-title":"Kidney Int"},{"key":"2026010204362462000_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore no bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2026010204362462000_bib15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00395-025-01115-y","article-title":"Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium","volume":"120","author":"Wang","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"2026010204362462000_bib16","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.molmet.2021.101337","article-title":"Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment","volume":"54","author":"D\u2019Onofrio","year":"2021","journal-title":"Mol Genet Metab"},{"key":"2026010204362462000_bib17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2025","journal-title":"Cardiovasc Res"},{"key":"2026010204362462000_bib18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2026010204362462000_bib19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3\u2013mediated protection on microvascular endothelial cells and reduction of oxidative stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"2026010204362462000_bib20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"key":"2026010204362462000_bib21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacbts.2024.08.003","article-title":"Empagliflozin in acute myocardial infarction reduces no-reflow and preserves cardiac function by preventing endothelial damage","volume":"10","author":"Nikolaou","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"2026010204362462000_bib22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am J Hypertens"},{"key":"2026010204362462000_bib23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic communication by SGLT2 inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"2026010204362462000_bib24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.15252\/emmm.201707604","article-title":"GDF15 is a heart-derived hormone that regulates body growth","volume":"9","author":"Wang","year":"2017","journal-title":"EMBO Mol Med"},{"key":"2026010204362462000_bib25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin Chem"},{"key":"2026010204362462000_bib26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000455907","article-title":"Association of growth differentiation factor 15 with mortality in a prospective hemodialysis cohort","volume":"7","author":"You","year":"2017","journal-title":"Cardiorenal Med"},{"key":"2026010204362462000_bib27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/ndt\/gfr575","article-title":"Macrophage inhibitory cytokine-1 (MIC-1\/GDF15) and mortality in end-stage renal disease","volume":"27","author":"Breit","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026010204362462000_bib28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2026010204362462000_bib29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/jama.2024.16338","article-title":"Dialysis for chronic kidney failure. A review","volume":"332","author":"Flythe","year":"2024","journal-title":"JAMA"},{"key":"2026010204362462000_bib30","doi-asserted-by":"publisher","first-page":"sfae405","DOI":"10.1093\/ckj\/sfae405","article-title":"The ERA Registry Annual Report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons","volume":"18","author":"Boenink","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026010204362462000_bib31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","article-title":"Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients","volume":"18","author":"Barreto","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026010204362462000_bib32","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-025-00760-x","article-title":"Safety and short-term effects of empagliflozin in patients with heart failure and end-stage renal disease","volume":"25","author":"Lin","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026010204362462000_bib33","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3390\/biomedicines11071908","article-title":"Efficacy and safety of the use of SGLT2 inhibitors in patients on incremental hemodialysis: maximizing residual renal function, is there a role for SGLT2 inhibitors?","volume":"11","author":"De","year":"2023","journal-title":"Biomedicines"},{"key":"2026010204362462000_bib34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/ndt\/gfac274","article-title":"Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis","volume":"38","author":"Caton","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026010204362462000_bib35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.kint.2016.02.037","article-title":"Preservation of residual kidney function in hemodialysis patients: reviving an old concept","volume":"90","author":"Mathew","year":"2016","journal-title":"Kidney Int"},{"key":"2026010204362462000_bib36","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.ekir.2023.07.020","article-title":"Residual kidney function and cause-specific mortality among incident hemodialysis patients","volume":"8","author":"Okazaki","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026010204362462000_bib37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12933-024-02424-7","article-title":"Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026010204362462000_bib38","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010204362462000_bib39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/08968608221096556","article-title":"The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients","volume":"43","author":"Borkum","year":"2023","journal-title":"Perit Dial Int"},{"key":"2026010204362462000_bib40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11906-024-01314-3","article-title":"Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease?","volume":"26","author":"Siddiqui","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2026010204362462000_bib41","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/medicina60081198","article-title":"Effects of Sodium-Glucose Cotransporter 2 inhibitors in diabetic and non-diabetic patients with advanced chronic kidney disease in peritoneal dialysis on residual kidney function: in real-world data","volume":"60","author":"Moral Berrio","year":"2024","journal-title":"Medicina"},{"key":"2026010204362462000_bib42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12882-024-03683-y","article-title":"SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study","volume":"25","author":"Lai","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026010204362462000_bib43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-023-03429-2","article-title":"Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function","volume":"25","author":"Hamdan","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026010204362462000_bib44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.09.049","article-title":"Empagliflozin and ultrafiltration volume in patients undergoing peritoneal dialysis","author":"Doi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026010204362462000_bib45","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1046\/j.1523-1755.1998.00899.x","article-title":"Expression of glucose transporters in human peritoneal mesothelial cells","volume":"53","author":"Schr\u00f6ppel","year":"1998","journal-title":"Kidney Int"},{"key":"2026010204362462000_bib46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000520894","article-title":"Peritoneal expression of SGLT-2, GLUT1, and GLUT3 in peritoneal dialysis patients","volume":"47","author":"Schricker","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"2026010204362462000_bib47","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/biom10111573","article-title":"SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate","volume":"10","author":"Balzer","year":"2020","journal-title":"Biomolecules"},{"key":"2026010204362462000_bib48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lfs.2016.07.018","article-title":"Diabetes and exposure to peritoneal dialysis solutions alter tight junction proteins and glucose transporters of rat peritoneal mesothelial cells","volume":"161","author":"Debray-Garc\u00eda\u2008Y","year":"2016","journal-title":"Life Sci"},{"key":"2026010204362462000_bib49","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.biopha.2018.10.106","article-title":"SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2","volume":"109","author":"Zhou","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2026010204362462000_bib50","doi-asserted-by":"publisher","first-page":"107374","DOI":"10.1016\/j.intimp.2021.107374","article-title":"Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-\u03b2\/Smad signaling","volume":"93","author":"Shentu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2026010204362462000_bib51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/08968608231165865","article-title":"Blockade of sodium-glucose co-transporters improves peritoneal ultrafiltration in uraemic rodent models","volume":"44","author":"Vorobiov","year":"2024","journal-title":"Perit Dial Int"},{"key":"2026010204362462000_bib52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/08968608211008095","article-title":"SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis","volume":"41","author":"Martus","year":"2021","journal-title":"Perit Dial Int"},{"key":"2026010204362462000_bib53","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1681\/ASN.2022040474","article-title":"Phloretin improves ultrafiltration and reduces glucose absorption during peritoneal dialysis in rats","volume":"33","author":"Bergling","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026010204362462000_bib54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/08968608221080170","article-title":"Dual SGLT1\/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis","volume":"43","author":"Martus","year":"2023","journal-title":"Perit Dial Int"},{"key":"2026010204362462000_bib55","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1681\/ASN.2022070841","article-title":"The sweet science of glucose transport","volume":"33","author":"Sridhar","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026010204362462000_bib56","doi-asserted-by":"crossref","first-page":"914","DOI":"10.34067\/KID.0000000717","article-title":"Dose-response relationship of phloretin therapy on water and glucose transport during experimental peritoneal dialysis","volume":"6","author":"Bj\u00f6rk","year":"2025","journal-title":"Kidney 360"},{"key":"2026010204362462000_bib57","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026010204362462000_bib58","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/14740338.2024.2412228","article-title":"Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design","volume":"24","author":"Barreto","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026010204362462000_bib59","doi-asserted-by":"publisher","first-page":"e087617","DOI":"10.1136\/bmjopen-2024-087617","article-title":"Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial","volume":"14","author":"Yan","year":"2024","journal-title":"BMJ Open"},{"key":"2026010204362462000_bib60","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2025yem71v7w","article-title":"Effects of Henagliflozin on cardiac structure in patients with heart failure with preserved ejection fraction undergoing dialysis: the HELD-HF randomized controlled trial: TH-OR049","volume":"36","author":"Lu","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026010204362462000_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semnephrol.2016.12.002","article-title":"Evolution of cardiovascular disease during the transition to end-stage renal disease","volume":"37","author":"Bansal","year":"2017","journal-title":"Semin Nephrol"},{"key":"2026010204362462000_bib62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.ajkd.2018.02.363","article-title":"Evolution of echocardiographic measures of cardiac disease from CKD to ESRD and risk of all-cause mortality: findings from the CRIC Study","volume":"72","author":"Bansal","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026010204362462000_bib63","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ki.2013.252","article-title":"Worldwide, mortality risk is high soon after initiation of hemodialysis","volume":"85","author":"Robinson","year":"2014","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf350\/65290012\/sfaf350.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/1\/sfaf350\/65290012\/sfaf350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/1\/sfaf350\/65290012\/sfaf350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T09:36:29Z","timestamp":1767346589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf350\/8323150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf350","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,14]]},"article-number":"sfaf350"}}